FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.
What happened
FDA inspected MMC Healthcare Ltd.'s drug manufacturing facility at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024. FDA found process validation reports with added data, backdated signatures, and replaced pages; a UV-Vis (ultraviolet-visible) computer system used for release testing lacked an audit trail (a record of changes) and defined user access levels. FDA also found microbial test methods that differed from USP (United States Pharmacopeia) methods and lacked validation data.
What FDA found
The quality unit did not have adequate authority or controls, as shown by process validation reports with added data, backdated signatures, and replaced pages.
21 CFR 211.22(a)The ultraviolet-visible (UV-Vis) computer system used for release testing lacked an audit trail (a record of changes) and defined user access levels.
21 CFR 211.68(b)The company did not use USP (United States Pharmacopeia) methods for multiple products and could not provide data showing its alternate methods were validated or equivalent.
21 CFR 211.165(e)
What FDA wants
FDA asks MMC to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. If it cannot complete corrective actions in that time, it must state why and give a completion schedule.
Who should pay attention
- brands and distributors that buy MMC drug products
- drug manufacturers that rely on paper or electronic records for release testing
- quality teams at India-based contract manufacturers
This is a summary. Read the original letter on fda.gov.